LocalMed in licensing talks for PerfusaSleeve angioplasty perfusion technology.
This article was originally published in The Gray Sheet
LOCALMED PERFUSASLEEVE OFFERS LOWER-COST PERFUSION CATHETER than devices sold by market leader Advanced Cardiovascular Systems, LocalMed President and CEO Paul Goeld told investors at the recent UBS Securities life sciences conference in New York City. "The advantage of [PerfusaSleeve] is that we preserve the operator's choice of using high performance, low cost" percutaneous transluminal coronary angioplasty balloons. "In fact, the cost of our perfusion device along with the standard PTCA balloon is still far less than the cost of the perfusion balloon from ACS," Goeld claimed.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.